Syngene International reports a 3% year-on-year increase in revenue from operations for the nine months ending December 31, 2025, reaching ₹2,702 Cr. However, the company experienced a 3% decrease in revenue for the third quarter (Oct-Dec), with revenue declining to ₹917 Cr. The firm’s partnership with Bristol Myers Squibb was extended to 2035.
Financial Performance Overview
Syngene International announced its financial results, highlighting a mixed performance. The company’s revenue from operations for the nine months ended December 31, 2025, increased by 3% year-on-year to ₹2,702 Cr. However, third-quarter revenue witnessed a decrease of 3%, falling to ₹917 Cr.
Key Financial Highlights for Q3 FY26 (Oct-Dec 2025)
- Revenue from Operations: ₹917 Cr (down 3%)
- Reported EBITDA: ₹225 Cr (down 26%)
- Reported EBITDA Margin: 24%
- Reported PAT (before exceptional items): ₹73 Cr (down 44%)
- Reported PAT Margin: 8%
Key Financial Highlights for 9M FY26 (Apr-Dec 2025)
- Revenue from Operations: ₹2,702 Cr (up 3%)
- Reported EBITDA: ₹664 Cr (down 12%)
- Reported EBITDA Margin: 24%
- Reported PAT (before exceptional items): ₹227 Cr (down 22%)
- Reported PAT Margin: 8%
Strategic Developments
Syngene International extended its collaboration with Bristol Myers Squibb through to 2035, expanding the scope of integrated services across the drug development lifecycle.
Investments and Expansions
Syngene commissioned a new commercial-scale facility for liquid-filled hard gelatin capsules to strengthen its oral solid dosage (OSD) platform. The company also expanded advanced chemistry capabilities at its Hyderabad site.
Recognition
Syngene earned the prestigious 5S Certification for its Translational & Clinical Research unit and was ranked among the “World’s Best Companies in Sustainable Growth” list by TIME magazine and Statista.
Source: BSE
